

WORLD **VACCINE &**
 **IMMUNOTHERAPY**

CONGRESS
WEST COAST

1 - 3 December 2020
Virtual Live Event

**Integrating the technologies revolutionising
immunotherapy and its impact on
vaccine development**



Pre-Congress Webinars



Dr Leonard Friedland
VP, Scientific Affairs
and Public Health
Vaccines, North
America
GSK



Prof Bali Pulendran
Professor,
Department of
Pathology &
Laboratory Medicine
Stanford University




Dr Jerald Sadoff
Senior Advisor
Janssen
Infectious
Diseases and
Vaccines



Dr Theresa Lavallee
Vice President,
Translational Medicine
Parker Institute for
Cancer
Immunotherapy



Dr Steven Reed, CEO,
HDT Bio



Dr BIOL. SCI.
Alessandro Sette
Center Head, Division
Head, & Professor Center
for Infectious Disease
La Jolla Institute



Dr Karin Jooss
Executive Vice
President of
Research & Chief
Scientific Officer
Gritstone
Oncology



Dr Roy Baynes
Senior Vice
President Global
Clinical
Development
and Chief
Medical Officer
Merck Research
Laboratories



Dr Peter Hotez
Dean, National
School of Tropical
Medicine, Director
Texas Children's
Hospital Center,
Baylor College of
Medicine



**Dr Martina
Sersch, CMO,**
Gracell



Dr Wayne C. Koff
President and
CEO
The Human
Vaccines Project



**Dr Maria
Karasarides, Vice
President, Head
Early Assets &
Biomarkers, BMS**

Digital Agenda

Tuesday 1st December Agenda (PACIFIC TIME ZONE)

Morning Networking 08:00 – 9:00

Morning plenary sessions 9:00 – 11:00

9:00 Welcoming remarks and introduction to congress

09:00 Opening Keynote panel: SARS-CoV-2 – Are we in sight of a vaccine? What now?

- In the absence of an immediate vaccine – what have we learnt about dealing with the next pandemic X?
- What more is needed to enhance public health support?
 - Effective communication strategies
- Tools to achieve harmonization of safety data collection across vaccine candidates to maximize their comparability and value
- Addressing safety concerns and hesitancy
- The path to regulatory approval – EUAs, speed of trials, incorporating RWD into RCTs

Moderator: Dr Maria Elena Bottazzi, Co-Director, Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine

Dr Peter Hotez, MD, PhD, FASTMH, FAAP, Dean, National School of Tropical Medicine, Co-Director, Texas Children's Hospital Center for Vaccine Development

Dr Jeff Roberts, Associate Director for Scientific Affairs, OVR, FDA

Dr Farshad Guirakhoo, CSO, COVAXX

Invited: Dr Patrick Zuber, Group Leader, Global Vaccine Safety, WHO

10:15 Keynote presentation: PD-1 antibodies are transforming and hold great promise for cancer treatments both as mono and combination therapies

- PD-1 monotherapy has shown broad activity across tumor types and lines of therapy
- Precision Medicine tools have been deployed to enrich monotherapy studies and to inform combination therapies
- PD-1 antibodies in combination are showing significant activity across tumor types and lines of therapy
- Such approaches are showing great promise in the neoadjuvant and adjuvant settings
- An extensive clinical data base is allowing rapid evaluation of various precision medicine generated hypotheses

Dr Roy Baynes, Senior Vice President Global Clinical Development and Chief Medical Officer, Merck Research Laboratories

11:00 Rapid manufacture of vaccines for pandemic response – are we prepared for commercial manufacture of SARS-CoV-2 vaccines?

- Unique challenges associated with different vaccine platforms, DNA, RNA, non-replicating viral vector, recombinant protein etc.
- Considerations for moving from clinical to commercial production
- Scale-up strategies - how long it will take to produce vaccines at sufficient scale to meet global demand?
- Currently available capacity and potential future capacity required for the suite of vaccine platforms and technologies

Dr Andreas Kuhn, Senior Vice President RNA Biochemistry & Manufacturing, BioNTech

Invited: Moderator: David Robinson, Deputy Director, CMC Vaccines Development and Surveillance, BGMF

Digital Agenda

Invited: Dr Robert J Jubba, Vice President, Biological Manufacturing and Clinical Supply Management, Inovio Pharmaceuticals

Invited: Dr Brian Webb, Senior Vice President, Manufacturing, NovaVax

Invited: Moderna, Sanofi, GSK, COVAXX

Exhibition Hall & Partnering 12:00 – 13:30

1:30 - 3:00

Choose and switch between our parallel sessions

Vaccine Development

New Technology

Cancer Immunotherapy

Immune Profiling & Translational Science

Exhibition Hall & Partnering 3:00 – 3:40

3:40 – 5:10

Choose and switch between our parallel sessions

Vaccine Development

New Technology

Immune Profiling & Translational Science

Cancer Immunotherapy

Exhibition Hall & Partnering 5:10 – 6:00

Wednesday 2nd December Agenda (PACIFIC TIME ZONE)

Exhibition Hall & Partnering 08:00 – 9:00

Morning plenary sessions 9:00 – 11:30

Welcome back to day 2

09:00 Keynote Presentation: Rapid discovery and testing technologies for human monoclonal antibodies for infectious diseases: the watershed moment of SARS-CoV-2

[Dr James Crowe](#), Director, Vanderbilt Vaccine Center, [Vanderbilt University Medical Center](#)

Follow-up interview with [Dr Douglas Richman](#), M.D., Director, Center for Aids Research, [University of California, San Diego](#)

10:00 Keynote presentation: Using surveillance to inform the future of vaccine development

Digital Agenda

Bonnie Maldonado, Professor of Pediatrics and of Epidemiology and Population Health, Chief, Division of Pediatric Infectious Diseases, **Stanford University School of Medicine**

10:30 Keynote Interview: Recent breakthroughs in translational & pre-clinical oncology and their implications for the field

Interviewer: Dr Theresa LaVallee, VP Translational Medicine, **Parker Institute for Cancer Immunotherapy**

Dr Priti Hedge, CSO, **Foundation Medicine**

Dr Raluca Verona, Head of Immune Oncology Translational Research, **Janssen Pharmaceutical Companies of Johnson & Johnson**

Invited: Dr Philip Greenberg, M.D., Professor & Head, Program in Immunology, Clinical Research Division, Fred Hutch

Exhibition & Partnering 11:30 -12:30

12:30 - 2:00

Choose and switch between our parallel sessions

Vaccine Development

Bioprocessing & Manufacture

Immune Profiling & Translational Science

Engaging T-cells & Combinations

Exhibition & Partnering 2:00- 3:00

3:00 – 4:30

Choose and switch between our parallel sessions

Exhibition & Partnering 4:30 – 5:00

Thursday 3rd December Agenda (PACIFIC TIME ZONE)

Morning Networking 08:00 – 9:00

Morning plenary sessions 9:00 – 11:00

Opening Remarks:

09:00 Live Panel: Pharmaceutical perspective; The future of vaccine policy

-How address the increased public focus of vaccine safety

-Expanding the immunization schedule to fit different populations and age groups

-how to incorporate new vaccines into the existing routine immunization schedule

-Immunization priorities and new vaccine strategies

Julia Spencer, Associate Vice President, Global Vaccines Public Policy, Partnerships, & Government Affairs, **Merck**

Digital Agenda

Theodore Tsai, Vice President of Immunizations Science and Policy, Takeda Vaccines – invited
Michael Greenberg, Vice President and head of Medical Strategy, Sanofi Pasteur – invited

10:15 The microbiome & the immune system – implications for cancer immunotherapy

Dr Ami Bhatt, Assistant Professor, Medicine (Hematology) & Genetics, Stanford University

Exhibition Hall & Partnering 11:00 – 12:40

12:40 – 2:40

Choose and switch between our parallel sessions

Partnerships & Funding

Clinical Development & Trials

Engineered cancer therapies

Exhibition Hall & Partnering 2:40 – 3:10

Choose and switch between our parallel sessions 3:10 – 4:50

Partnerships & Funding

Clinical Development & Trials

Engineered cancer therapies

Closing Plenary Session 4:50 – 5:30

4.40 AI vs Pandemics: The role of AI in the covid-19 response and lessons for future pandemic response

Dr Jason Paragas, Former Director of Innovation, Lawrence Livermore National Laboratory

END OF DIGITAL CONGRESS

Digital Agenda

Vaccine Development

Tuesday 1st December

1:00 Intro to channel
Bacterial Vaccine Development
1:00 MAPS vaccine program for streptococcus pneumoniae <i>Frank Malinoski, Senior Vice President, Clinical Development and Regulatory Affairs, Affinivax - TBC</i>
1:30 Broad-spectrum pneumococcal conjugate vaccine <i>Jim Wassil, COO, Vaxcyte</i>
2:00 A phase II vaccine candidate against Clostridium Difficile <i>Shon A Remich, Senior Director, Vaccine Clinical Research and Development, Pfizer</i>
2:30 Vaccine development to reduce the recurrences of Urinary Tract Infections (UTI) <i>Gary Eldridge, President and CEO, Sequoia</i>
3:00 – 3:40 Exhibition Hall & Partnering
COVID-19 Vaccine Development
3:40 Live PANEL: Late stage COVID-19 vaccine development – phase 3 trials and beyond <i>To invite: Inovio, Moderna, NovaVax, BioNTech, Pfizer, Vaxart Sinovac, AZ</i>
5:10 – 6:00 Exhibition Hall & Partnering

Wednesday 2nd December

12:30 Intro to channel
Respiratory Disease Vaccine Development
12:30 Influenza vaccine with extended protection <i>Dr Mario Barro AVP, Head of Advanced Research, FluNTX/ Sanofi Pasteur</i>
1:00 MVX01: A global, serotype-independent, pneumococcal protein fusion vaccine candidate <i>Kevin Killeen, CSO, Matrivax</i>
1:30 Nanoparticle VLP-based vaccine for RSV <i>Douglas Holtzman, Chief Scientific Officer, Icosavax – invited</i>

Digital Agenda

2:00 – 3:00 Exhibition Hall & Partnering
Emerging & Re-emerging Diseases
3:00 Progress in development of CHIKV VLP vaccine Sarah Royalty Tredo , Director, Emergent BioSolutions
3:30 Zika Vaccine Development: Current Status Inna Ovsyannikova , Professor of Medicine, Mayo Clinic Rochester
4:00 Phase I trials for Marburg vaccine
4:30 – 5:00 Exhibition Hall & Partnering

Digital Agenda

New Technology

Tuesday 1st December

1:00 Intro to channel
1:00 Panel: Advancing immune research in space Rachel Clemens , Commercial Innovation Manager, Center for the Advancement of Science in Space <i>More panelists TBC</i>
2:00 Tech Showcase - Virus and Vaccine Research & Development David Apiyo , Senior Manager, Applications, ForteBio (Sartorius)
2:30 Polyclonal antibody treatments for respiratory diseases Ashley Wozniak , Director, Marketing and Plasma Products, Emergent BioSolutions
3:00 – 3:40 Exhibition Hall & Partnering
3:40 Immunoinformatics tools for the design of epitope driven vaccines * Session title TBC Lenny Moise , Director of Vaccine Research, EpiVax Inc
4:10 Rational design of a hepatitis C virus vaccine and use of a novel immunoadjuvant delivery system Dr Thomas Fuerst , Professor and Director, University of Maryland
4:40 Tech Showcase - Structural vaccinology for viral vaccine design
5:10 – 6:00 Exhibition Hall & Partnering

Digital Agenda

Cancer Immunotherapy

Tuesday 1st December – Cancer vaccines & Neoantigens

1:00 Introduction to channel
1:00 New generation of antigen-tailored dendritic cell (DC) vaccines to activate potent immune responses Dr Christiane Geiger , Director Cell Therapy Process Development, Medigene
1:30 Development of neoantigen based monoclonal antibodies to target tumors Dr Philip Arlen , CSO, Precision Biologics
2:00 Panel: Approaches to targeted therapies and cancer vaccination – what’s working? <ul style="list-style-type: none">• DNA / Peptides /Dendritic cells as an approach to cancer vaccines• Different ways to look at neoantigens - How do we decide on the best target for each modality?<ul style="list-style-type: none">○ Using algorithms? Other methods?• Cancer vaccines are being driven towards neoantigens – balancing more effective vaccine and manufacturability<ul style="list-style-type: none">○ What have we learnt from recent NeoAg therapy trials? What is missing? Dr Karin Jooss , CSO, Gritstone Oncology Dr Olja Finn , Distinguished Professor, Department of Immunology, University of Pittsburgh School of Medicine Dr Lisa Butterfield , Vice President, Research and Development, Parker Institute for Cancer Immunotherapy Dr Jessica Flechtner , CSO, Genocea Biosciences
3:00 – 3:40 Exhibition Hall & Partnering
3:40 Interview: Can cancer vaccines hold their promise? Interviewer: Dr Lauren Wood , CMO, PDS Biotech Dr Lei Zheng , Co-director, Pancreatic Cancer Precision Medicine Center of Excellence Program, Johns Hopkins School of Medicine Dr Bernard Fox , Harder Family Endowed Chair for Cancer Research Member and Chief, Lab of Molecular and Tumor Immunology, Providence Cancer Center ; CEO, Ubivac
4:25 Clinical updates in the development of personalized cancer immunotherapies
4:50 DNA cancer vaccines for HPV & non-HPV associated cancers Dr Jeffrey Skolnik , Senior Vice President of Clinical Development, Immuno-Oncology, Inovio Pharmaceuticals
5:15 – 6:00 Exhibition Hall & Partnering

Digital Agenda

Wednesday 2nd December – Engaging T-cells

12:30 Chair's opening remarks
T-cell engaging therapies
12:30 Development of Bavixiumab in combination with pembrolizumab for advance gastric or gastroesophageal cancer Senior Representative, OncXerna
1:10 Design and development of a selective IL-2 fusion protein ALKS4230 as a monotherapy or in combination with CPI Dr Jessica Rege, Vice President, Head of Oncology, Alkermes
1:40 First-in-class oral t-cell activators adapted to target a wide range of cancer-related antigens Dr Marc Mansour, CSO, Vaximm
2:10 – 3:00 Exhibition Hall & Partnering
3:00 Panel: Engaging T-cells and beyond – what are the gaps in our knowledge and how do we move beyond them? <ul style="list-style-type: none">• What do we mean by T-cell engagement, what are the gaps in our knowledge?• Other important cell types – exploring macrophages / B-cells• What data is lacking? Moderator: Dr Maria Karasarides, Vice President, Early Assets & Biomarkers, BMS Dr David Schaer, Director, Translational Oncology, Pfizer Dr Michaela Bowden, Director Translational Oncology, BMS Dr John Connolly, CSO, Parker Institute for Cancer Immunotherapy
4:00 IgM antibody technology platform for development t-cell engaging therapies Dr Bruce Keyt, CMO, IGM Biosciences
4:20 Combining therapeutic “dark antigens” to create off-the-shelf therapeutic cancer vaccines Invited: Dr Peter Mason, Head of Product Platform Science and Technology, Enara Bio
4:40 – 5:00 Exhibition Hall & Partnering

Digital Agenda

Thursday 3rd December – Engineered Cancer Therapies

12:40 Chair's opening remarks
12:40 TCR therapy clinical development talks
1.10 Clinical development of CAR-T & TCR therapies against a variety of cancer types <i>Invited: Dr Mihail Obrocea, Senior Director, Juno Therapeutics (BMS)</i>
1:40 DEACT – A unique approach to adoptive cell therapy <i>Invited: Dr Richard Koya, Co-Founder & CSO, Tactiva Therapeutics</i>
2:10
2:40 – 3:10 Exhibition Hall & Partnering
3:10 Live Panel: Where are we going? CAR-T & TCR therapy development beyond 2020
<ul style="list-style-type: none">• How has the pandemic affected R&D and Clinical trials?• New targets – what are the most promising new targets?<ul style="list-style-type: none">○ Dual targeted CAR-Ts○ Targeting solid tumors• Faster manufacture – what are the current bottle necks to faster manufacture?• Driving down costs – how can we keep novel therapies affordable?
Moderator: Dr Martina Sersch, CMO, Gracell
Dr Chris Bond, VP, Cell Engineering, Kite, a Gilead Company
Dr Pascal Touchon, President & CEO, Atara Bio
Dr Cheng Liu, Founder & CEO, Eureka Therapeutics
Dr Aiman Shalabi, VP, Vice President, R&D, Cell & Gene Therapies (NYESO), GSK
Closing Plenary sessions 4:40 – 5:50

Digital Agenda

Immune Profiling & Translational Science

Tuesday 1st December –

1:00 Intro to Immune Profiling
Profiling Covid-19 Immunity
1:00 Live Panel: Advancing the uses and applications of TCR-Repertoire sequencing for infectious diseases & cancer – can it broaden our thinking about COVID-19 immunity? <ul style="list-style-type: none">Recent advances in quantifying and characterizing TCRs and BCRsMapping TCRs to antigens<ul style="list-style-type: none">What are the challenges?How can we improve accuracy?What is the quality of the data?The application of TCR sequencing to improve cancer immunotherapyThe application of TCR sequencing to understanding immunity to SARS-CoV-2 <p>Dr Mark Davis, Director of the Stanford Institute for Immunology, Transplantation and Infection, Stanford University Dr Morten Nielsen, Group Leader, Professor, Department of Health Technology · Bioinformatics · Immunoinformatics and Machine Learning, Technical University of Denmark Dr Lindsay Cowell, Associate Professor, Population & Data Sciences, UT Southwestern Dr Jamie K. Scott, Professor Emerita, Health Sciences, Simon Fraser University Dr Sharon Benzeno, Chief Business Development Officer, Adaptive Biotechnologies</p>
<ul style="list-style-type: none">2:00 Immune recognition of SARS CoV2 epitopes in exposed and unexposed individuals Dr Alessandro Sette, Center Head, Division Head, and Professor Center for Infectious Disease, LaJolla Institute2:20 T cell and antibody responses to SARS-CoV-2 and the immune basis for different disease outcomes in acute COVID-19 Dr Shane Crotty, Professor, Division of Vaccine Discovery, LaJolla Institute
2:40 Immune profiling studies informing better vaccine & immunotherapy design <i>*session title TBC</i> Dr Harlan Robins , CSO, Adaptive Biotech
3:05 – 3:40 Exhibition Hall & Partnering
3:40 Advances in immune-monitoring and clinical diagnostics for Covid-19 and other infectious diseases Senior Representative, Viracor Eurofins

Digital Agenda

4:05 High resolution analysis of antibody epitope repertoire dynamics in covid-19: a path towards understanding individual responses and personalized disease assessment

[John Shon, CTO, Serimmune](#)

4:20 Broad and prevalent sars-cov-2 CD8+ T cell response in recovered covid-19 individuals demonstrates kinetics of early differentiation

[Dr Michael Fehlings, Co-founder / Director Scientific Affairs, ImmunoScape](#)

4:45 *Progress in measuring cell mediated immunity for drug discovery* *TBC

[Dr Magdalena Tary-Lehmann M.D., Ph.D., Chief Scientific Officer, Immunospot \(CTL\)](#)

5:00 – 6:00 Exhibition Hall & Partnering

Wednesday 2nd December

12:30 Intro to channel

12:30 Development of next generation multiplex assays providing a more comprehensive view of immune status

[Senior Representative, Luminex Corp](#)

1:00 What anti-viral immune responses may teach us about anti-cancer immunity

- CMV and HIV evoke T cells responses, but they differ in magnitude, phenotype, and function
- CD8+ IL-2-producing T cells may be critical to protection
- Similar findings in CTLA4-based immunotherapy trials: CD8+ IL-2+ or CD8+ effector memory T cell frequencies correlate with response
- Possibility of boosting the CD8 memory T cell pool if needed, e.g. with mTOR inhibitor

[Dr Holden Maecker, Professor \(Res\), Microbiology & Immunology, Director, Human Immune Monitoring Center, Stanford University](#)

1:30 Targeting neoantigens for cancer immunotherapy

[Dr Mahesh Yadav, Research and Early Development Scientist, Genentech](#)

2:00 – 3:00 Exhibition Hall & Partnering

Digital Agenda

Bioprocessing & Manufacture

Wednesday 2nd December

12:30 Intro to channel
12:30 Accelerating vaccine process development and increasing productivity with single use intensified processing and predictive process control - Downstream processing Senior Representative, Sartorius Stedim
1:00 Rationally engineered carrier proteins for mucosal vaccine development Krishna Prasad, Founder, Citranvi Biosciences
1:30 Advancing therapies with mRNA Nate Spangler, Director of Innovation & Strategy, Aldevron
2:00 – 3:00 Exhibition Hall & Partnering
3:00 Developing scalable manufacturing platforms for viral vectors Reserved, Univercells
3:30 New frontiers in bioengineered therapeutics: bridging science fiction with reality Michael Mitchell, Skirkanich Assistant Professor of Innovation, Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania
4:00 Panel: Mistakes in early to mid-stage vaccine development and how to avoid them <ul style="list-style-type: none">• When should you engage with the FDA – what are they looking for?• Balancing process control vs analytical development• Insurance of process control – what will satisfy the FDA downstream?• What should you prioritize?• Will you be able to commercialize without need for bridging studies? Jim Wassil, COO, Vaxcyte <i>Additional panelists TBC</i>
4:30 – 5:00 Exhibition Hall & Partnering

Digital Agenda

Clinical Development & Trials

Thursday 3rd December

12:40 Intro to channel
12:40 How to ensure quality in fast-enrolling vaccine trials <i>Lilith Mist, Executive Director, ID & Vaccine, Global Clinical Trial Operations, North America, Merck</i>
1:10 Harnessing digital health technologies: How vaccines can lead the way to accelerate virtual clinical trial adoption <i>David Jackson, Medical Research Clinician, Neuroscience, Lundbeck</i>
1:40 Different non-human primate models used for Tuberculosis studies, a TB case study <i>Patricia Darrah Head of Tuberculosis Vaccine Research Unit, VRC/NIH – invited</i>
2:10 Precision medicine: How are next-generation sequencing and adaptive studies changing the way clinical trials are done <i>Dr Apostolia Tsimberidou, Tenured Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center – TBC</i>
2:40 – 3:10 Exhibition Hall & Partnering
3:10 Live Panel: Ethical and clinical challenges associated with maternal immunization studies <i>Dr Mark Schleiss Professor, Department of Pediatrics, Division of Infectious Diseases and Immunology, Minnesota Medical School and Masonic Children's Hospital</i> <i>Dr Flor Munoz, Associate Professor, Baylor College of Medicine</i> <i>Pedro Moro, Medical Epidemiologist, Immunization Safety Office, Centers for Disease Control and Prevention</i> <i>Raphael Simon Senior Director, Bacterial Vaccines, Pfizer – invited</i>
Closing Plenary sessions 4:40 – 5:50

Digital Agenda

Partnerships & Funding

Thursday 3rd December

12:40 Intro to channel
12:40 Live Panel: Why is investing in immunization so important? -Current investments -Identification of projects -How to get funding for your vaccine Jenny Yip, Managing Partner, Adjuvant Capital Samuel Lee, Life Sciences Principal, CincyTech David Allison, Partner, Sam – invited Mike Powell, Managing General Partner, Sofinnova Investments – invited
14:00 Technology commercialization; getting your vaccine to the market and making it profitable Michael Salgaller, Supervisor, Invention Development and Marketing Unit, NCI/ NIH
2:40 – 3:10 Exhibition Hall & Partnering
3:10 Interview: How incubators support next generation life science start-ups Jeff Calcagno, Interim Head, LABS – invited
3:40 How to build sustainable, strong and successful business relationships with big pharma Christopher Tan, Director, Business Development and Licensing, Search and Evaluation, Infectious Diseases and Vaccines, Merck
4:10 One Health approach; why invest one health projects and how to get funding
Closing Plenary sessions 4:40 – 5:50